Premium
Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph‐negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI‐571 therapy
Author(s) -
Lewalle Philippe,
Meuleman Nathalie,
Verhest Alain,
Bron Dominique,
Martiat Philippe
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03542.x
Subject(s) - aplasia , medicine , pancytopenia , stem cell , haematopoiesis , peripheral blood stem cells , bone marrow aplasia , immunology , gastroenterology , surgery , bone marrow , hematopoietic stem cell transplantation , transplantation , biology , genetics
Summary. In advanced chronic myeloid leukaemia patients, STI‐571 produces complete haematological response in most cases and cytogenetic response in up to 50%. However, these patients often suffer periods of pancytopenia, which can lead to life‐threatening complications, and is probably due to the small number of residual normal stem cells. We have re‐infused peripheral blood stem cells collected at diagnosis, in a patient, while maintaining STI‐571 treatment. The patient recovered from aplasia, with Philadelphia‐negative haematopoiesis. Discontinuing an effective treatment because of persistent aplasia is a major concern; this method circumvents this problem inpatients who have undergone a stem cell harvest at diagnosis.